Category: Treatments

Treatment of autoimmune encephalitis with immune based therapies

The Journal of Neurology, Neuroscience, and Psychiatry reports on autoimmune encephalitis patients treated with immune based therapy including rituximab.  Authors Dowland F, Swayne A, Bhuta S, et. al. discuss three cases and conclude, “The field of neuro-immunology has seen a plethora of newly discovered autoantibodies, yet there remain a significant number of patients, with features suggestive …

Read more

FDA approves drug for relapsing forms of multiple sclerosis – possible implications for autoimmune encephalitis?

Medpage Today reports that the FDA has approved the biologic drug ocrelizumab (Ocrevus) for treatment of relapsing forms of multiple sclerosis. Ocrelizumab is an anti-CD20 monoclonal antibody targeting B cells which is the same mechanism of action as rituximab (Rituxan), which some earlier studies found to be effective against both relapsing-remitting and progressive MS. Off-label use of rituximab …

Read more

Bortezomib Treatment for Anti-NMDAR Autoimmune Encephalitis

The Journal of the American Medical Association Nuerology reports the following by authors Volker Behrendt, MD1; Christos Krogias, MD1; Anke Reinacher-Schick, MD2; Ralf Gold, MD1; and Ingo Kleiter, MD1: Anti-NMDAR  autoimmune encephalitis, associated with ovarian teratoma, predominantly affects young females.1 Because antibodies against subunits of the NMDAR contribute to the pathogenesis, methods targeting humoral immunity are therapeutically efficacious.2 However, some patients have an unsatisfactory outcome after high-dose corticosteroids, apheresis …

Read more

New treatment for anti-NMDAR autoimmune encephalitis reports Charité – Universitätsmedizin Berlin

One of the one of the largest university hospitals in Europe, Charite’, recorded significant progress in treating anti-NMDAR, including in patients who did not previously respond to treatment. Anti-NMDA receptor encephalitis is an inflammatory disease that affects the central nervous system. It is a rare autoimmune disease that results in the body producing antibodies against …

Read more

Autoimmune Encephalitis Alliance and Option Care co-sponsoring Mayo Clinic Trial on IVIg

The Autoimmune Encephalitis Alliance and Option Care Enterprises, Inc. are co-sponsoring a clinical trial at Mayo Clinic to evaluate intravenous immunoglobulin (IVIG) treatment in patients with autoimmune epilepsy who fail to benefit from standard epilepsy medications. This study, the first of its kind, builds on Mayo Clinic research advances identifying new approaches to the diagnosis and treatment …

Read more

Autoimmune Encephalitis Alliance co-sponsors pediatric AE treatment consensus meeting

The Autoimmune Encephalitis Alliance, along with Children’s National Health System, and the Childhood Arthritis and Rheumatology Research Alliance, co-sponsored the first International Pediatric Autoimmune Encephalitis Treatment Consensus Meeting at the Carnegie Endowment for International Peace in Washington, DC, on November 14. “The AE Alliance was honored to help bring many of the world’s leading experts …

Read more

“No miracle, just our brain” by Jules Morgan

Neuroplasticity is the brain’s ability to reorganize itself by forming new neural connections, allowing neurons (nerve cells) in the brain to compensate for injury and disease and to adjust their activities in response to new situations or to changes in their environment. The following is from an article in The Lancet Neurology. Written by Jules Morgan, “No …

Read more

Do you have experience with Rituximab/Rituxan as treatment for autoimmune encephalitis?

One of the most frequent requests we receive from patients/caregivers seeks greater information on the use of Rituximab (trade name is Rituxan). Are you a caregiver, recovering patient, or physician that has experience with the use of Rituximab as a treatment for AE that you believe would benefit others? There are two ways you can help. 1) Share …

Read more